ALLO
Allogene Therapeutics, Inc. Healthcare - Biotechnology Investor Relations →
Allogene Therapeutics, Inc. (ALLO) closed at $2.07 as of 2026-03-20, trading 51.8% below its 200-week moving average of $4.30. This places ALLO in the extreme value zone. The stock is currently moving closer to the line, down from -44.5% last week. The 14-week RSI sits at 60, indicating neutral momentum.
A big spike in selling this week — 2.1x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.
Over the past 340 weeks of data, ALLO has crossed below its 200-week moving average 6 times. On average, these episodes lasted 48 weeks. The average one-year return after crossing below was -4.6%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $465 million, ALLO is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -53.4%. The stock trades at 1.6x book value.
Share count has increased 55.6% over three years, indicating dilution.
Over the past 6.6 years, a hypothetical investment of $100 in ALLO would have grown to $8, compared to $241 for the S&P 500. ALLO has returned -32.3% annualized vs 14.3% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ALLO vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ALLO Crosses Below the Line?
Across 6 historical episodes, buying ALLO when it crossed below its 200-week moving average produced an average return of -17.2% after 12 months (median -3.0%), compared to +17.8% for the S&P 500 over the same periods. 33% of those episodes were profitable after one year. After 24 months, the average return was -52.0% vs +29.3% for the index.
Each line shows $100 invested at the moment ALLO crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
ALLO has crossed below its 200-week MA 6 times with an average 1-year return of +-4.6% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 2019 | Oct 2019 | 4 | 11.1% | +35.9% | -92.4% |
| Nov 2019 | Nov 2019 | 3 | 3.3% | +1.8% | -92.4% |
| Dec 2019 | Apr 2020 | 18 | 30.4% | +1.2% | -92.4% |
| Nov 2020 | Nov 2020 | 1 | 7.5% | -27.6% | -92.6% |
| Dec 2020 | Jan 2021 | 5 | 15.9% | -34.2% | -92.5% |
| May 2021 | Ongoing | 255+ | 86.8% | Ongoing | -93.1% |
| Average | 48 | — | +-4.6% | — |
Frequently Asked Questions
Is ALLO below its 200-week moving average?
Yes. As of 2026-03-20, Allogene Therapeutics, Inc. (ALLO) is trading 51.8% below its 200-week moving average of $4.30. The current price is $2.07.
What is ALLO's 200-week moving average price?
Allogene Therapeutics, Inc.'s 200-week moving average is $4.30 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ALLO drops below its 200-week moving average?
ALLO has crossed below its 200-week moving average 6 times in our data. The average one-year return after these crossings was -4.6%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 48 weeks on average.
Is ALLO a good value right now?
Here's what our data says about ALLO as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 60. Free cash flow is currently negative. Return on equity is -53.4%. Price-to-book is 1.6x. This is not a buy or sell recommendation — always do your own research.
How does ALLO compare to the S&P 500?
Over the past 6.6 years, $100 invested in ALLO would have grown to $8, compared to $241 for the S&P 500. That's -32.3% annualized vs 14.3% for the index. ALLO has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20